Jonathan L. Kaufman, MD | Authors

Articles

Venetoclax for Multiple Myeloma: The Phase 3 BELLINI Trial

April 18, 2022

Sponsored in Part by AbbVie/Content Independently Developed by Targeted Oncology. Dr. Shaji Kumar reviews data from his BELLINI clinical trial studying venetoclax paired with bortezomib and dexamethasone for multiple myeloma treatment.